Hongwei Shen

Zhongshan Second Road 58
Guangzhou, 510700, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Retraction Note: The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.

Retraction Note: The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 26, 2025

Correction: FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

Correction: FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

Journal: Oncogenesis

Published: March 16, 2023

Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity.

Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity.

Journal: Journal of advanced research

Published: June 05, 2021

Correction to: FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

Correction to: FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

Journal: Oncogenesis

Published: February 11, 2021

FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.

Journal: Oncogenesis

Published: June 20, 2020

Correction: High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis.

Correction: High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis.

Journal: Oncotarget

Published: March 14, 2020

PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer.

PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer.

Journal: Molecular therapy oncolytics

Published: March 14, 2020

The role of a semi-automated NanoVelcro system in capturing circulating tumor cells and evaluating their prognostic value for gestational choriocarcinoma.

The role of a semi-automated NanoVelcro system in capturing circulating tumor cells and evaluating their prognostic value for gestational choriocarcinoma.

Journal: Biomaterials science

Published: January 19, 2019

Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer.

Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer.

Journal: The Tohoku journal of experimental medicine

Published: July 03, 2018

Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.

Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.

Journal: International journal of cancer

Published: December 23, 2017

miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.

miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.

Journal: International journal of oncology

Published: July 31, 2017

The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.

The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 20, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026